Contact-Level ABM: Targeting the Key Individuals Within Accounts 

Most ABM programs target accounts. The best ABM programs target people.

Targeting people, on the surface, sounds opposite from the purpose of "account-based" marketing. In reality it's not - it's targeting the right people at the right accounts. This, i actuality, is the goal of account based marketing. In ABM, we're targeting into and selling to specific accounts, but it's people that make the purchasing decisions. The better we can connect with the right people, the more effective our marketing and sales can be.

Account-level targeting, which serves ads to all employees at a specified set of companies, is a meaningful improvement over broadcasting to the open market. But it still leaves a gap between the audience your budget is reaching and the audience that actually matters for a deal - those key purchasing decision-markers. Contact-level ABM closes that gap.

This post explains what contact-level ABM is, why it represents a genuine upgrade in precision over standard account-level targeting, and which tools are enabling it in B2B life sciences today.

The Limitations of Account-Level Targeting

When a standard ABM program runs programmatic display advertising to a target account list, the targeting mechanism works at the domain or IP address level. The platform identifies devices associated with the target company's network and serves ads to them. The benefit of account-level programmatic advertising is that there is a strong possibility that your ad content is seen by the right people at that company. The downside, though, is that your ads are also being seen many people at that company — finance staff, HR, IT, facilities, legal — who have no relevance to your solution.

Even layering in title or function targeting on LinkedIn, which significantly improves precision, is an approximation. Targeting "Senior Directors and above in Clinical Operations at your target account list" will reach a useful audience, but it will also include people adjacent to the buying committee, exclude buying committee members with non-standard titles, and provide no visibility into which specific individuals are engaging.

Therefore, if you know specific people to target at an account, using broad level account targeting is inefficient. You end up with significant ad spend reaching large numbers of people who will never influence a purchasing decision, while the specific individuals who will are reached only intermittently and without the individual-level visibility that would make outreach actionable.

Account-level targeting has genuine and strong commercial benefit. But for the highest-priority accounts and personas, account-level targeting limits the ability to prioritize getting in front of the right people.

What Contact-Level ABM Does Differently

Contact-level ABM operates from a fundamentally different starting point: instead of targeting a domain or an IP range, it targets a curated list of specific, named individuals.

Using email addresses, names, or device ID matching, contact-level ABM platforms serve ads directly to identified individuals. These are the exact people you have determined are most likely to be members of the buying committee at your target accounts. Your budget in contact-level ABM is spent almost entirely on those specific people, rather than on the broader organizational population.

The precision has two important consequences.

First, efficiency improves dramatically. When your advertising reaches a list of 200 named individuals across 40 target accounts (those most likely to have some say or level of interest in your solution) every impression has much higher relevance. There is limited waste of the kind built into account-level programmatic targeting.

Second, and more importantly for the commercial team, the engagement data becomes individually actionable. In account-level ABM, you might know that three people at a target biotech have clicked on your ads this month, but you may not know who they are, what their roles are, or whether they may be part of an-market buying group. In contact-level ABM, you know that the VP of Translational Medicine clicked twice, the Clinical Program Director clicked four times and visited the content page, and the Head of Procurement opened the email sequence. That is a buying committee picture, not an account-level signal, and it significantly changes how the sales team is empowered to engage with a target account.

How Contact-Level Targeting Works

Contact-level ABM platforms work by matching the contacts on your list to real, observable individuals as they browse the web. When a contact on your list visits a property within the platform's publisher network, the platform recognizes them through email address matching, device ID resolution, or identity graph lookups, and serves your ad to that specific person. The matching happens behind the scenes; from the contact's perspective, they simply see a relevant ad while going about their normal browsing behavior.

Because recognition and serving happen at the individual level, the engagement data the platform returns is correspondingly granular. Marketers and SDRs can see, for each specific contact, how many impressions they received, which ads they engaged with, what content they interacted with downstream, and how their engagement has trended over time. That individual-level record is what makes contact-level ABM commercially actionable in a way that account-level targeting generally isn't.

The practical implication for the sales team is significant. Instead of receiving a notification that "someone at Acme Biotech has been active this week" and having to investigate who that might be, the SDR receives a list of named individuals along with titles, content histories, and engagement frequencies. This is highly useful information that helps the SDR develop a plan for who to call, in what order, and what messaging to focus on. The quality of that first outreach conversation improves substantially when it can open with specific relevance rather than a more generic pitch.

Contact-level platforms also integrate with CRM and marketing automation systems, meaning engagement signals flow automatically into the tools the commercial team is already using. A contact who crosses a defined engagement threshold can trigger an SDR task, a lead score update, or an account elevation without requiring manual review of campaign data.

Building the Right Contact List: Where the Real Work Happens

Contact-level targeting is only as powerful as the list it operates from. Precision targeting of the wrong people produces precise data about irrelevant engagement. The effort invested in constructing a high-quality contact list is what determines whether a contact-level ABM program generates genuine commercial intelligence or merely impressive-looking metrics.

In life sciences, building that list well requires assembling intelligence from several distinct sources and using each to inform the others.

1. Start with Life-Science-Specific Intent Signals to Identify the Right Accounts

Before identifying specific contacts, the first question is: which accounts are most likely to be in an active buying cycle right now? In life sciences, the answer comes not from keyword-based web intent data (the signal type that general-purpose ABM platforms are built around) but from events that are predictive of near-term purchasing need.

A new clinical trial registration indicates that a specific program is advancing and that buying groups are likely forming around the services and capabilities needed to execute it. An IND filing signals that a program is preparing for first-in-human work, with all the operational and scientific purchasing that entails. A Series C or D funding round typically precedes acceleration of program investment and vendor engagement. A regulatory designation — Fast Track, Breakthrough Therapy, Orphan Drug — can compress timelines and create urgent purchasing needs. A new partnership or licensing deal may bring capital and new program activity simultaneously.

These events are publicly available and systematically trackable through clinical trial registries, regulatory submission databases, SEC filings, and life-science-specific pipeline intelligence platforms. Organizations that build their target account lists from these signals, rather than from generic web intent data, are starting from a fundamentally stronger intelligence position. The accounts they target are not just companies that look like good fits on paper; they are companies with a demonstrable, time-stamped reason to be in-market for a relevant solution.

2. Map the Right Personas for Each Account Type

With a target account list grounded in life-science-specific intent, the next step is determining which individuals within those accounts belong on the contact list. This is where persona mapping does its most important work.

A well-constructed persona map for a given ICP segment documents the titles, functions, and seniority levels that typically appear on the buying committee for that type of purchase. It is typically built from the sales and BD team's accumulated knowledge of who is actually present when deals of a given type get evaluated and closed, and often can be validated against CRM data, which may list the titles for the primary and additional contacts at all past sales opportunities.

The persona map translates directly into search criteria: when using a contact database to find individuals at a target account, you are looking for people that match the titles and functions identified in the persona map. (Note that when doing bulk search based on titles, it can be helpful to include negative keywords to exclude certain roles.)

The persona map should also be differentiated by account type. The buying committee for a large pharma account and the buying committee for a Series B biotech may share some common roles but differ significantly in seniority, organizational structure, and the degree to which functions are centralized or distributed across programs.

3. Use Contact Databases to Find the Named Individuals

With target accounts identified through intent signals and target personas defined through the persona map, the final step in list construction is finding the specific named individuals who hold those roles at those accounts.

B2B contact databases, which are platforms that aggregate professional profile data including name, title, employer, email address, and seniority level, are the primary tool for this work. For life sciences, databases with strong coverage of the biotech and pharma sectors, regularly refreshed to account for the high rate of organizational change in this industry, are essential. A contact list built from data that is twelve months out of date in an environment where companies routinely restructure, merge, or reduce headcount is a list that will underperform.

The database search takes the persona map as its input and returns a set of matching individuals at each target account. That set is then cross-referenced with CRM contacts to elevate anyone the commercial team has already engaged, and matched against marketing data like prior campaign engagement data conference engagements, etc.

The resulting contact list is not a generic prospecting database. It is a curated set of individuals who work at accounts with documented reasons to be in-market, in roles that correspond to the buying committee for your specific solution type. When this list is used as the target list for contact-level ABM, your campaign is much more likely to generate the kind of engagement that directly supports your BD team and leads to pipeline and ultimately, strong ABM program ROI.